Grand rounds at the National Institutes of Health: HDAC inhibitors as radiation modifiers, from bench to clinic
about
Histone deacetylase inhibitors as radiosensitisers: effects on DNA damage signalling and repairAcetylation-mediated proteasomal degradation of core histones during DNA repair and spermatogenesis.Histone deacetylase activity selectively regulates notch-mediated smooth muscle differentiation in human vascular cells.Advances in epigenetic glioblastoma therapy.The possible prognostic role of histone deacetylase and transforming growth factor β/Smad signaling in high grade gliomas treated by radio-chemotherapy: a preliminary immunohistochemical studyGenome-wide association and pharmacological profiling of 29 anticancer agents using lymphoblastoid cell linesInteraction of radiation therapy with molecular targeted agentsMetabolic Effects of Known and Novel HDAC and SIRT Inhibitors in Glioblastomas Independently or Combined with TemozolomideNew perspectives of valproic acid in clinical practice.Biomarkers of histone deacetylase inhibitor activity in a phase 1 combined-modality study with radiotherapy.The challenges and the promise of molecular targeted therapy in malignant gliomas.Histone deacetylase inhibition sensitizes osteosarcoma to heavy ion radiotherapy.Valproic acid enhances the efficacy of radiation therapy by protecting normal hippocampal neurons and sensitizing malignant glioblastoma cells.BNIP3 acts as transcriptional repressor of death receptor-5 expression and prevents TRAIL-induced cell death in gliomasCombinatorial strategies for oncolytic herpes simplex virus therapy of brain tumors.Histone deacetylase inhibition and dietary short-chain Fatty acids.Histone deacetylase inhibitor, valproic acid, radiosensitizes the C6 glioma cell line in vitro.Sequence-Dependent Radiosensitization of Histone Deacetylase Inhibitors Trichostatin A and SK-7041.NCoR controls glioblastoma tumor cell characteristics.Down-modulation of SEL1L, an unfolded protein response and endoplasmic reticulum-associated degradation protein, sensitizes glioma stem cells to the cytotoxic effect of valproic acid.Dual Functional Mesoporous Silicon Nanoparticles Enhance the Radiosensitivity of VPA in Glioblastoma.Valproic acid inhibits glioblastoma multiforme cell growth via paraoxonase 2 expression.Histone deacetylases and their role in asthma.Valproic acid for the treatment of malignant gliomas: review of the preclinical rationale and published clinical results.Targeting of histone deacetylases in brain tumors.Epigenetic therapy for solid tumors: from bench science to clinical trials.Antiepileptic drugs in patients with malignant brain tumor: beyond seizures and pharmacokinetics.Silencing of histone deacetylase 2 suppresses malignancy for proliferation, migration, and invasion of glioblastoma cells and enhances temozolomide sensitivity.Valproic acid modulates radiation-enhanced matrix metalloproteinase activity and invasion of breast cancer cells.Synthesis, Biological Evaluation, and Computer-Aided Drug Designing of New Derivatives of Hyperactive Suberoylanilide Hydroxamic Acid Histone Deacetylase Inhibitors.Radiosensitization by histone deacetylase inhibition in an osteosarcoma mouse model.EGFRvIII gene rearrangement is an early event in glioblastoma tumorigenesis and expression defines a hierarchy modulated by epigenetic mechanisms.Phase I/II Trial of Vorinostat Combined with Temozolomide and Radiation Therapy for Newly Diagnosed Glioblastoma: Final Results of Alliance N0874/ABTC 02.Combined treatment with D-allose, docetaxel and radiation inhibits the tumor growth in an in vivo model of head and neck cancer.Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi.Overview of the Classical Histone Deacetylase Enzymes and Histone Deacetylase Inhibitors
P2860
Q26863429-0501C776-83FA-4E5C-9562-F4E6857118F6Q27933881-DB4143C4-5C7E-46BC-8F71-9A8C32D7728DQ30424133-2394BF85-71C8-4962-8798-9212EEBD44B7Q33567030-F55E990A-DA6A-4A84-8D5D-F7265ED51EC4Q33712267-8C2D600A-45CF-4B85-B54B-2FD662419AC0Q33746404-3D19090F-5E67-48D5-9A03-019C58E76027Q34124285-C2764C63-1184-499B-895C-630688FC2739Q34318242-35A3B4BF-D301-41C7-B4F5-EC9E391A3270Q34380256-BFDD756B-F187-4B4E-B35F-608C1F29A7F7Q35108007-92310688-B268-4212-AFE3-45744AE739AFQ35214534-47B0E872-97C4-4D14-9388-E462C96ABDC7Q35856816-0F456E33-9643-4F76-B6F6-CFF400E9B930Q36544286-9C826245-2C3F-4110-BA8D-7D2F2EFF67BDQ36809469-1657CDF2-4F28-45F7-A864-DFD9F65F35C5Q36849213-8A601AAC-4F8E-43D5-924B-0CF27BBF4395Q36858061-BA288C4C-2D28-4931-B6DB-765251877FD9Q37388728-3B959E77-1A5E-4A13-9070-5053767F3C9EQ37484598-5ED96FEC-0D60-4946-B9F2-17B61B9EC2DCQ37492181-F57C6F51-E361-4A15-BDC3-72AD736A9790Q37536543-721CAADF-CFFF-47F9-AD23-C3CE4252070FQ37638111-9C157AA0-334F-43DD-87FF-4CF3D793CDF5Q37716414-87DC5E16-C110-4B78-ABB5-7D6623359B65Q37974680-FBFD51F1-4EDF-4118-92DA-E93D6E16A758Q38016227-0B9085FA-420D-4184-B8B1-34B6DFAC1D17Q38233117-621AD982-699F-4326-8EC1-AF4663665683Q38459836-F2B1D427-58B5-42EF-87A9-D38A5E90CE22Q38495389-144BFE70-6BF6-47AF-ACC5-88867606C5E1Q38731925-A05BE403-1BE2-46AB-8E28-6D235CA554E5Q38826037-47F1C79D-E194-4789-89BE-77B206019ED9Q38900826-FBFEFE2A-0C4B-4E5C-8864-2FFBBEC444ECQ39134963-5EAAB21E-230E-44F7-AC65-6CDCDD1331D8Q39314446-46C9ECF2-F736-485A-A844-B8205B929230Q42696115-466AB0C8-52E1-46AF-8B7E-C734C0B5938AQ49874995-08935985-16D5-4341-AB63-2CC0DB9D9E67Q52590685-FEB1DD5B-D836-4E6E-91E2-C73E51C6D40BQ58689803-03E20A21-A196-4FDE-A781-DA1A971CACC6
P2860
Grand rounds at the National Institutes of Health: HDAC inhibitors as radiation modifiers, from bench to clinic
description
2011 nî lūn-bûn
@nan
2011 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Grand rounds at the National I ...... odifiers, from bench to clinic
@ast
Grand rounds at the National I ...... odifiers, from bench to clinic
@en
type
label
Grand rounds at the National I ...... odifiers, from bench to clinic
@ast
Grand rounds at the National I ...... odifiers, from bench to clinic
@en
prefLabel
Grand rounds at the National I ...... odifiers, from bench to clinic
@ast
Grand rounds at the National I ...... odifiers, from bench to clinic
@en
P2093
P2860
P921
P1476
Grand rounds at the National I ...... odifiers, from bench to clinic
@en
P2093
Jacob E Shabason
Kevin Camphausen
Philip J Tofilon
P2860
P304
P356
10.1111/J.1582-4934.2011.01296.X
P577
2011-12-01T00:00:00Z